Liver Cancer/HCC
Liver Cancer/HCC
Antiviral Therapy for Hepatitis C, Especially with Sustained Response, Lowers Liver Cancer Risk
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 October 2012 00:00
- Written by Liz Highleyman
Interferon-based antiviral therapy lowers the likelihood that people with liver fibrosis or cirrhosis due to chronic hepatitis C will develop hepatocellular carcinoma (HCC), with the greatest risk reduction seen among those who achieve virological response, according to a study described in the October 22, 2012, edition of open-access online journal BMJ Open. 
EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 27 April 2012 00:00
- Written by Liz Highleyman
The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 03 January 2012 00:00
- Written by Press Release
Bristol-Meyers Squibb's investigational anti-cancer drug brivanib did not improve overall survival of patients with hepatocellular carcinoma (HCC) who were unable to take or did not respond to sorafenib (Nexavar) in the Phase 3 BRISK-PS trial, the company recently reported. The drug is still being tested in other patients populations.
Hepatitis B and C Are Major Causes of Liver Cancer in U.S.
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 10 January 2012 00:00
- Written by Press Release
Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major cause of hepatocellular carcinoma (HCC, a form of primary liver cancer) in the U.S., according to a study by researchers at the Mayo Clinic in Rochester, MN. A related analysis found that among immigrants from Somalia, hepatitis B and C were both significant causes of liver cancer.
AASLD 2011: Engineered Poxvirus Shows Promise for Treating Advanced Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 08 November 2011 00:00
- Written by Jennerex
A genetically engineered vaccinia poxvirus (JX-594) can rapidly destroy tumors and prolong survival of people with advanced hepatocellular carcinoma (HCC), according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
More Articles...
- Gene Variation Linked to Liver Cancer in Hepatitis C Patients
- Screening for Liver Cancer in HIV/HCV Coinfected People
- Chronic Hepatitis C Complications are Increasing, Especially among People Older than 60 Years
- A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy
Web Design and Development by